These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 18203324)

  • 1. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE; Gülfe A; Saxne T; Geborek P
    Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of psoriatic arthritis therapies.
    Gladman DD
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions.
    Blomqvist P; Feltelius N; Ekbom A; Klareskog L
    J Rheumatol; 2000 May; 27(5):1171-7. PubMed ID: 10813283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current concepts and new developments in the treatment of psoriatic arthritis.
    Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
    Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.
    Zink A; Thiele K; Huscher D; Listing J; Sieper J; Krause A; Gromnica-Ihle E; von Hinueber U; Wassenberg S; Genth E; Schneider M;
    J Rheumatol; 2006 Jan; 33(1):86-90. PubMed ID: 16395755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes.
    Chakravarty EF; Sanchez-Yamamoto D; Bush TM
    J Rheumatol; 2003 Feb; 30(2):241-6. PubMed ID: 12563675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
    Liang GC; Cordero M; Dyer A; Chang RW
    J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD.
    Cannon GW; Holden WL; Juhaeri J; Dai W; Scarazzini L; Stang P
    J Rheumatol; 2004 Oct; 31(10):1906-11. PubMed ID: 15468352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CORRONA database.
    Kremer JM
    Autoimmun Rev; 2006 Jan; 5(1):46-54. PubMed ID: 16338211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.
    Wolfe F; Caplan L; Michaud K
    Arthritis Rheum; 2006 Feb; 54(2):628-34. PubMed ID: 16447241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of treatment with infliximab on serum cytokine profile of patients with rheumatoid and psoriatic arthritis.
    Amital H; Barak V; Winkler RE; Rubinow A
    Ann N Y Acad Sci; 2007 Sep; 1110():649-60. PubMed ID: 17911480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating psoriatic arthritis: how effective are TNF antagonists?
    Gottlieb AB; Antoni CE
    Arthritis Res Ther; 2004; 6 Suppl 2(Suppl 2):S31-5. PubMed ID: 15228619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
    Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
    J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists.
    Pope JE; Hong P; Koehler BE
    J Rheumatol; 2002 Feb; 29(2):255-60. PubMed ID: 11838842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leflunomide-associated infections in rheumatoid arthritis.
    Jenks KA; Stamp LK; O'Donnell JL; Savage RL; Chapman PT
    J Rheumatol; 2007 Nov; 34(11):2201-3. PubMed ID: 17937473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients.
    Leeb BF; Andel I; Sautner J; Fassl C; Nothnagl T; Rintelen B
    Arthritis Rheum; 2007 Mar; 57(2):256-60. PubMed ID: 17330303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.